Abbott, Myriad extend alliance to further research on human genetic variation around drug targets

By E. Janene Geiss

Philadelphia, Nov. 22 - Myriad Genetics, Inc. said it has extended its strategic alliance in pharmacogenetics with Abbott Laboratories to continue research on identifying human genetic variation around drug targets in various stages of development.

Abbott will fund the research under this collaboration and Myriad will use its high-throughput sequencing technologies and proprietary mutation screening software to analyze samples from various populations to identify genetic polymorphisms, or differences in the DNA between individuals, officials said in a company news release.

The results of this collaboration may help Abbott's drug discovery programs develop drugs that will be the most effective for the widest range of patients, officials said.

"There is significant potential through this collaboration to develop new personalized medicine products in areas of important and growing health care needs," Myriad president and chief executive officer Peter Meldrum said in the release.

Myriad's technology and expertise are valuable to Abbott's drug discovery and development, said Brian Spear, Abbott's director of genomic and proteomic technologies, in the release.

Myriad is a Salt Lake City biopharmaceutical company focused on development of health care products.

Based in Abbott Park, Ill., Abbott is a global pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.